secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOVIE INC. (BIVI)
CIK:        0001580149
Form:       8-K
Filed at:   2022-12-06T23:59:59+00:00
Accession:  0001520138-22-000548
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioVie announces positive Phase 2 results for NE3107 in Parkinson's and Alzheimer's; epigenetic age reduced 3.3 years
--------------------------------------------------------------------------------

- PD trial: NE3107+levodopa improved UPDRS Part 3 by 3+ points vs levodopa alone; under-70 patients saw 6-point superiority.
- AD trial: 2.1-point improvement on ADAS-Cog12 (p=0.0173) in MCI/mild AD patients; CSF p-tau reduced by 1.66 pg/mL.
- 18 of 22 AD patients showed improvement on functional MRI; no drug-related adverse events reported.
- DNA methylation analysis: Horvath SkinBlood clock reduced by 3.3 years (p=0.0021) after 3 months; 19 of 22 patients showed reduction.
- Full Parkinson's data to be presented at AD/PD 2023 conference in March-April 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1580149/000152013822000548/0001520138-22-000548-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1580149/000152013822000548/bivi-20221205_8k.htm
  HTML page:      https://secwatch.observer/filing/0001520138-22-000548

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer